Diamyd Medical’s associated company Cellaviva is appointed European distributor for StemBioSys

Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) today announced
that its associated company Cellaviva AB has signed an agreement regarding the
European distribution rights for a stem cell product developed by StemBioSys,
Inc., a privatetly held biomedical company based in San Antonio, Texas, USA.
The agreement entails that Cellaviva becomes the exclusive distributor for
StemBioSys’ (www.stembiosys.com) products in Sweden and Denmark with non
-exclusive rights covering the rest of Europe. The agreement will initially
cover StemBioSys’ cell expansion product BM-HPME®. Future products may be added
to the agreement as they become available.

Additional information regarding the agreement will become available at
www.cellaviva.se

About Diamyd Medical
Diamyd Medical is dedicated to finding a cure for autoimmune diabetes through
pharmaceutical development and investments in stem cell and medical technology.

Diamyd Medical develops the diabetes vaccine Diamyd®, an Antigen Based Therapy
(ABT) based on the exclusively licensed GAD-molecule. The Company’s licensed
technologies for GABA and Gliadin have also potential to become key pieces of
the puzzle of a future solution to prevent, treat or cure autoimmune diabetes,
and also certain inflammatory diseases. At this time six clinical studies are
ongoing with Diamyd®. Diamyd Medical is one of the major shareholders in the
stem cell company Cellaviva AB. Stem cells can be expected to be used in
Personalized Regenerative Medicine (PRM), for example for restoration of beta
cell mass in diabetes patients where the autoimmune component of the disease has
been arrested. Diamyd Medical also has holdings in the medtech company Companion
Medical, Inc., San Diego, USA and in the gene therapy company Periphagen, Inc.,
Pittsburgh, USA.

Diamyd Medical’s B-share is traded on Nasdaq Stockholm First North under the
ticker DMYD B. Remium Nordic AB is the Company’s Certified Adviser.
For further information, please contact:
Ulf Hannelius, President and CEO
Phone: +46 736 35 42 41. E-mail: ulf.hannelius@diamyd.com
Diamyd Medical AB (publ)
Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8
661 63 68
E-mail: info@diamyd.com. Reg. no.: 556242-3797. Website: www.diamyd.com.